13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Exploring the pharma-VC relationship: How do they build complementary investment strategies?

Edition

Exploring the pharma-VC relationship: How do they build complementary investment strategies?

Pharma and VC firms have a symbiotic relationship, with VCs providing crucial funding to startups, and pharmaceutical companies offering strategic partnerships and potential acquisition opportunities. How do they align their investment strategies to maximize mutual benefits? How do pharma and VC firms manage their differing risk appetites and investment timeframes? What approaches do pharma and VC firms take to due diligence and decision-making processes? What is the place for the corporate VCs in the relationship?

Moderator: Bart Wuurman, CEO, Apaxen

Florence Dal Degan

Senior Director, External Innovation
France
Ipsen

Maya Chkaiban

Associate
France
Jeito

Nuno Alves

Associate Director, Innovation Management
United Kingdom
Astellas Europe

Tugrul Ozdemir

Associate
Denmark
Novo Holdings
Scroll to Top
  • No products in the cart.